Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
United Therapeutics Corporation director Christopher Causey reported an option exercise and share sale. On January 6, 2026, he exercised stock options for 1,000 shares of common stock at an exercise price of $119.76 per share and acquired the underlying shares.
On the same date, he sold 1,000 shares of United Therapeutics common stock at a reported price of $510 per share. After these transactions, he directly owned 4,190 shares of common stock and 7,320 stock options. The filing notes that the option exercise and sale were carried out under a Rule 10b5-1 trading plan adopted on September 30, 2025.
A shareholder has filed a notice of proposed sale under Rule 144 for 1,000 shares of common stock of the issuer, to be sold through Morgan Stanley Smith Barney LLC on or about 01/06/2026 on the NASDAQ. The filing lists an aggregate market value of 510000.00 for these shares and notes that 43056599 shares of the issuer’s common stock were outstanding.
The 1,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from the issuer, paid in cash. The notice also reports that the same seller disposed of an additional 1,000 common shares on 01/02/2026 for 500014.60 in gross proceeds during the past three months. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer.
United Therapeutics Corporation’s CFO and Treasurer reported an option exercise and related share sales. On December 15, 2025, the executive exercised stock options for 3,517 shares of common stock at an exercise price of $146.03 per share and acquired those shares.
On the same date, the executive sold United Therapeutics common stock in multiple open-market transactions, with disclosed weighted average sale prices including $491.525 and $500.303 per share. After these transactions, the executive directly beneficially owns 8,142 shares of United Therapeutics common stock.
The option exercise and subsequent sales were carried out pursuant to a Rule 10b5-1 trading plan entered into on August 5, 2025. The report also corrects a prior administrative error by now including 24 shares acquired on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan in the executive’s reported holdings.
United Therapeutics’ Chairperson & CEO, who is also a director, reported stock option exercises and related common stock sales under a pre-arranged Rule 10b5-1 trading plan. On December 15 and 16, 2025, the reporting person exercised 4,000 stock options at an exercise price of $120.26 on each day and sold the resulting shares in multiple open-market transactions at prices including $491.77, $495.1384, $492.4938, $494 and $497.17.
After these transactions, the reporting person held 130 shares of common stock directly, plus indirect holdings of 166 shares through a spouse and additional shares through family trusts, including 324,518, 258,117, 45,596 and 10,962 shares. The trades were made pursuant to a 10b5-1 trading plan entered on May 2, 2025, which will continue until the earlier of the exhaustion of a 294,000-share stock option tranche expiring on March 15, 2026 or December 31, 2025.
United Therapeutics President and COO reported insider transactions on 12/15/2025. The filing shows exercises of stock options into 14,625 and 7,875 shares of common stock held in family-related trusts, at exercise prices of $117.76 and $146.03 per share.
The common shares were then sold the same day in multiple trades under a Rule 10b5-1 trading plan entered on June 3, 2025, including sales at weighted average prices of $491.1817 and $500.3052. After these transactions, the trusts reported no remaining common shares, while 141,000 and 6,190 stock options remain indirectly owned.
United Therapeutics Corporation director reports stock option exercise and share sale. On 12/15/2025, the reporting person exercised 1,000 stock options at an exercise price of $101.80 per share and acquired an equal number of United Therapeutics common shares. On the same date, they sold 1,000 shares of common stock at a weighted average price of $495.9539 per share, with individual trades executed between $495.64 and $496.09. Following these transactions, the director beneficially owns 2,490 shares directly and 1,100 shares indirectly through a trust, as well as 3,910 stock options with a $101.80 exercise price expiring on 06/21/2026.
United Therapeutics reported that a company director sold 50 shares of common stock on 12/11/2025 at a price of $482.98 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that the insider entered into on September 11, 2025. Following this sale, the director beneficially owns 470 shares of United Therapeutics common stock held directly.
United Therapeutics Corp’s Executive Vice President and General Counsel reported an insider transaction involving stock options and common shares. On 12/11/2025, the officer exercised stock options for 11,000 shares of common stock at an exercise price of $146.03 per share and then sold common stock in several market transactions at weighted average prices including $482.2219 and $487.366 per share.
The activity was carried out under a pre-arranged Rule 10b5-1 trading plan that the reporting person entered into on December 24, 2024. After these transactions, the officer directly owned 36,781 shares of United Therapeutics common stock and held 20,250 stock options that remain outstanding.
United Therapeutics Corporation’s chairperson and CEO reported option exercises and related share sales in December 2025. On 12/11/2025 and 12/12/2025, the reporting person exercised stock options for 4,000 shares of common stock on each day at an exercise price of $120.26 per share and sold the same number of shares in the market.
The reported sales were executed at weighted average prices of $483.1213, $484.3036, $485.14, $489.9533 and $490.9772, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025. Following these transactions, the reporting person holds 130 shares directly, 166 shares indirectly through a spouse, and additional indirect interests through several family trusts, including positions of 324,518, 258,117, 45,596 and 10,962 shares.
United Therapeutics Corporation reported insider activity by its CFO and Treasurer involving stock options and common shares. On 12/08/2025, the officer exercised a stock option for 21,000 shares of common stock at an exercise price of $146.03 per share, increasing direct holdings before sales.
That same day, the officer sold United Therapeutics common stock in a series of open-market transactions coded as sales, with weighted average prices reported from about $475.08 to $486.71 per share, executed in multiple trades at price ranges disclosed in the notes. After these transactions, the officer directly owned 8,142 shares of common stock. The filing states that the option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 5, 2025.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
